LEO Pharma A S, a global company focused on medical dermatology, announced that it will present 23 scientific posters at Maui Derm Hawaii 2026, taking place from January 25 to 29. The presentations highlight a broad range of evidence across multiple dermatologic conditions, including atopic dermatitis, chronic hand eczema, generalized pustular psoriasis, and pyoderma gangrenosum. The posters feature clinical trial findings, real world data, and U S focused analyses that reflect the company’s continued investment in advancing dermatology research.
Health Technology Insights: AHN Offers Innovative Low-Dose Radiation Therapy for Osteoarthritis
The scientific content includes patient reported outcomes, long term follow up results, and health economic evaluations related to ADBRY tralokinumab ldrm and ANZUPGO delgocitinib cream. In addition, LEO Pharma will share findings from a post marketing study assessing the effectiveness of SPEVIGO spesolimab sbzo. These presentations build on the momentum from Winter Clinical Hawaii, where the company previously showcased 22 posters.
According to LEO Pharma, the combined data demonstrate ongoing progress in expanding medical understanding of chronic skin diseases and reinforce the company’s role in driving innovation within dermatology. The studies are designed to address both clinical outcomes and real world challenges faced by patients and healthcare providers.
Health Technology Insights: CareTrust Acquires $142 Million Mid-Atlantic Nursing Portfolio
Shannon Schneider, Vice President of North America Medical Affairs at LEO Pharma, said the new findings further strengthen the company’s growing evidence base in dermatology. She explained that the research reflects LEO Pharma’s commitment to developing treatments for chronic skin conditions while recognizing how symptoms such as itching, pain, and reduced daily functioning can significantly affect patients’ lives.
Among the key findings to be presented is the final analysis of a 52 week real world study evaluating patient reported outcomes in U S adults with moderate to severe atopic dermatitis treated with ADBRY. The company will also share early real world data on the safety and effectiveness of SPEVIGO for generalized pustular psoriasis flares. Several posters will focus on the lived experience of patients with moderate to severe chronic hand eczema in the United States, including outcomes following treatment with ANZUPGO cream. Additional analyses will provide U S focused health economic insights to support payer and practice level decision making for both atopic dermatitis and chronic hand eczema.
Chronic hand eczema is a condition in which symptoms persist for more than three months or recur multiple times within a year. It is one of the most common skin disorders affecting the hands and can become long lasting for many patients. In the United States, it affects roughly one in ten adults and is marked by symptoms such as itching, pain, redness, scaling, and cracking of the skin. The condition is linked to skin barrier disruption, inflammation, and changes in the skin microbiome. Chronic hand eczema can significantly affect quality of life, with many patients reporting difficulty performing daily activities and experiencing negative effects on work and income.
Atopic dermatitis is a chronic inflammatory skin disease characterized by intense itching and recurring skin lesions. It develops due to a combination of skin barrier dysfunction and immune system imbalance, which leads to ongoing inflammation. Certain immune signaling pathways, including those involving IL 13, are known to play a central role in disease development, along with other inflammatory factors that contribute to persistent symptoms.
Through its presence at Maui Derm Hawaii 2026, LEO Pharma aims to share meaningful scientific insights and support continued improvements in the care of people living with complex skin diseases.
Health Technology Insights: Natera Launches 21-Gene Fetal Focus Single-Gene NIPT
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
